Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Nature CommunicationsOpen Access

LYMTACs:chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization and degradation

View Full Paper
Ask AI
Bookmark
Share

Authors

DNDhanusha A. NalawanshaGMGeorgios MazisGHGitte Husemoen

Discussion

Loading...

Member takes

Overview

This study demonstrates that LYMTACs regulate oncogenic signaling through lysosomal membrane proteins, suggesting a novel approach for cancer therapy.

Key Points

  • LYMTACs effectively target membrane proteins for lysosomal degradation, enhancing therapeutic potential in cancer.
  • A promiscuous kinase inhibitor-based LYMTAC shows significant inhibition of oncogenic KRASG12D signaling.
  • The approach harnesses multi-pharmacology to facilitate both target relocalization and degradation across various lysosomal membrane proteins.
  • LYMTACs represent a promising platform for accessing challenging membrane proteins within cellular pathways.

Cite This Study

Nalawansha et al. (2025) studied this question.

synapsesocial.com/papers/68c242e0b210217d647a4d80https://doi.org/10.1038/s41467-025-63128-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Small-Molecule Ligands Targeting Lysosome-Shuttling Receptors and the Emerging Landscape of Lysosome-Targeting Chimeras2025
  2. 2An Engineered Nanovesicles-Based Lysosome-Targeting Protein Degradation Platform (NV-TACs) for Cancer Immunotherapy2026
  3. 3Development of LYTACs via incorporating a nucleolin-targeting and lysosome-directed aptamer2025
  4. 4Molecular engineering of lysosome-based degraders unveils a rapidly expanding therapeutic strategy2026
  5. 5Macropinocytosis-Mediated Recyclable LYTACs (McR-TACs) for Membrane and Extracellular Protein Degradation2025